GlassScriptPhysician profile
Lacey Vence
NPI 1841600350
$5,464.48
in general payments reported to CMS, 2019-2025
32 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $523 · 2021: $560 · 2022: $676 · 2023: $926 · 2024: $1,009 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,908 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,907.95 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,134.21 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $697.54 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $413.83 | 2019-2025 | Aklief, Dysport, Nemluvio |
| Lilly USA, LLC | $407.27 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $370.96 | 2022-2025 | Odomzo, Blu-U, Winlevi |
| Amgen INC. | $325.14 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $301.84 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $225.82 | 2019-2025 | Dupixent |
| Genzyme Corporation | $220.27 | 2019-2024 | |
| Leo Pharma INC. | $185.92 | 2019-2024 | Adbry |
| Pfizer INC. | $170.61 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $155.25 | 2019-2025 | Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $137.28 | 2022-2024 | Sotyktu |
| Incyte Corporation | $81.59 | 2022-2024 | Opzelura |
| Biofrontera INC. | $77.13 | 2019-2023 | Xepi, Bf-Rhodoled, Ameluz |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $72.34 | 2019-2025 | |
| Allergan, INC. | $71.15 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $61.26 | 2023-2025 | Zoryve |
| Ucb, INC. | $43.39 | 2019-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.20 | 2023-2024 | Spevigo |
| Fresenius Kabi USA, LLC | $40.10 | 2023-2024 | Idacio |
| Organon LLC | $38.40 | 2025 | Vtama |
| Merck Sharp & Dohme LLC | $29.52 | 2019 | |
| Sebela Pharmaceuticals INC. | $25.34 | 2019 | |
| Mayne Pharma Commercial LLC | $22.03 | 2019 | |
| Dermavant Sciences, INC. | $20.85 | 2023 | Vtama |
| Verrica Pharmaceuticals INC. | $20.16 | 2023 | Ycanth |
| Almirall LLC | $17.52 | 2021 | |
| Organogenesis INC. | $17.28 | 2025 | Novachor |
| Krystal Biotech INC | $15.14 | 2023 | Vyjuvek |
| Stemline Therapeutics INC. | $14.30 | 2022 | |
| Prugen, INC. Pharmaceuticals | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacey Vence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.